Document Detail


Plasma interferon-gamma-inducible protein-10 (IP-10) levels during acute hepatitis C virus infection.
MedLine Citation:
PMID:  23325615     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Systemic levels of interferon-gamma-inducible protein-10 (IP-10) are predictive of treatment-induced clearance in chronic hepatitis C virus (HCV). In the present study, factors associated with plasma IP-10 levels at the time of acute HCV detection and the association between IP-10 levels and spontaneous clearance were assessed in three cohorts of acute HCV infection. Among 299 individuals, 245 (181 male, 47 human immunodeficiency virus-positive [HIV+]) were HCV RNA+ at acute HCV detection. In adjusted analysis, factors independently associated with IP-10 levels ≥150 pg/mL (median level) included HCV RNA levels >6 log IU/mL, HIV coinfection and non-Aboriginal ethnicity. Among 245 HCV RNA+ at acute HCV detection, 214 were untreated (n = 137) or had persistent infection (infection duration ≥26 weeks) at treatment initiation (n = 77). Spontaneous clearance occurred in 14% (29 of 214). Individuals without spontaneous clearance had significantly higher mean plasma IP-10 levels at the time of acute HCV detection than those with clearance (248 ± 32 versus 142 ± 22 pg/mL, P = 0.008). The proportion of individuals with spontaneous clearance was 0% (0 of 22, P = 0.048) and 16% (27 of 165) and in those with and without plasma IP-10 levels ≥380 pg/mL. In adjusted analyses, favorable IL28B genotype was associated with spontaneous clearance, while higher HCV RNA level was independently associated with lower odds of spontaneous clearance. Conclusion: High IP-10 levels at acute HCV detection were associated with failure to spontaneously clear HCV. Patients with acute HCV and high baseline IP-10 levels, particularly >380 pg/mL, should be considered for early therapeutic intervention, and those with low levels should defer therapy for potential spontaneous clearance. (HEPATOLOGY 2013;).
Authors:
Jason Grebely; Jordan J Feld; Tanya Applegate; Gail V Matthews; Margaret Hellard; Alana Sherker; Kathy Petoumenos; Geng Zang; Ineke Shaw; Barbara Yeung; Jacob George; Suzy Teutsch; John M Kaldor; Vera Cherepanov; Julie Bruneau; Naglaa H Shoukry; Andrew R Lloyd; Gregory J Dore
Related Documents :
7489625 - A sonographic-pathological correlation of liver biopsies in patients with the acquired ...
24750255 - Hla-dq polymorphisms with hbv infection: different outcomes upon infection and prognosi...
24373085 - Hbsag quantification: useful for monitoring natural history and treatment outcome.
23053555 - Exclusive breastfeeding reduces risk of mortality in infants up to 6 mo of age born to ...
11149025 - Spontaneous bacterial peritonitis in saudi arabian patients with non-alcoholic liver ci...
24183185 - The holy grail: the search for undiagnosed cases is paramount in improving the cascade ...
Publication Detail:
Type:  Clinical Trial; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't     Date:  2013-05-08
Journal Detail:
Title:  Hepatology (Baltimore, Md.)     Volume:  57     ISSN:  1527-3350     ISO Abbreviation:  Hepatology     Publication Date:  2013 Jun 
Date Detail:
Created Date:  2013-06-13     Completed Date:  2013-08-16     Revised Date:  2014-06-03    
Medline Journal Info:
Nlm Unique ID:  8302946     Medline TA:  Hepatology     Country:  United States    
Other Details:
Languages:  eng     Pagination:  2124-34     Citation Subset:  IM    
Copyright Information:
Copyright © 2013 American Association for the Study of Liver Diseases.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Biological Markers / blood
Chemokine CXCL10 / blood*
Female
Hepatitis C / blood*,  virology
Humans
Logistic Models
Male
RNA, Viral / blood*
Young Adult
Grant Support
ID/Acronym/Agency:
HEO-115696//Canadian Institutes of Health Research; MOP-106468//Canadian Institutes of Health Research; R01 DA 15999-01/DA/NIDA NIH HHS; R01 DA015999/DA/NIDA NIH HHS
Chemical
Reg. No./Substance:
0/Biological Markers; 0/Chemokine CXCL10; 0/RNA, Viral
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Screening for genetic variants in BDNF that contribute to childhood obesity.
Next Document:  Palladium- and Nickel-Catalyzed Alkenylation of Enolates.